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Abstract: Cholesterol and triglycerides, important lipid constituents of cell, are essential to carry out several vital physio-
logical functions. Lipids might be associated with cancers because they play a key role in the maintenance of cell integ-
rity. The pathway for cholesterol synthesis may also produce various tumorigenic compounds and cholesterol serves as a 
precursor for the synthesis of many sex hormones linked to increased risk of various cancers. In some malignant diseases, 
blood cholesterol undergoes early and significant changes. The mechanism for the link between cancer and cholesterol 
remains controversial. The dates from studies are confusing because both hypolipidemia and hypercholesterolemia might 
be connected with malignancy. Not only cancers but also antineoplastic therapies have an influence on lipid profile. There 
are also dates suggesting that antihyperlipemic drugs might nfluenced malignancy.  
Keywords: Cancer, dyslipidemia, cholesterol, statins.  
BACKGROUND 
  Cholesterol and triglycerides are important lipid constitu-
ents of the cell. They play key roles in many vital physio-
logical functions. Cholesterol is vital in the maintenance of 
the structure and functional integrity of all biological mem-
branes. It is also involved in various other biological func-
tions including; cell growth and division of both normal and 
malignant tissue, the activity of membrane bound enzymes 
and stabilizing the DNA double helix.  
  Cellular uptake and regulation of cholesterol is mediated 
by lipoprotein receptors located on the cell surface. In 
plasma, triglycerides and cholesterol are packaged into lipo-
proteins. These lipoproteins are then taken up and degraded 
by the cells. In some malignant diseases it has been demon-
strated that blood cholesterol levels are significantly altered 
[1]. It has been proposed that low or high levels of choles-
terol in the proliferating tissues and in blood could be reflect 
a role in carcinogenesis [1].  
  Lipids might be associated with cancers as they have an 
integral role in the maintenance of cell integrity. Although, 
raised lipids are strongly associated with the pathogenesis of 
coronary heart disease, researchers have also reported an 
association between plasma/serum lipids and lipoproteins 
with different types of cancers [2-4].  
  The main question is to whether hypolipidemia predis-
poses to cancer or is an effect of the malignancy. Data from 
studies are conflicting as not only hypolipidemia but also 
hypercholesterolemia might be connected with malignancy.  
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Furthermore, antineoplastic therapies have an influence on 
lipid profile.  
THE LEVEL OF CHOLESTEROL FRACTIONS AND 
CANCERS 
  The exact mechanisms by which lipids and lipoproteins 
may contribute to carcinogenesis are not clearly understood. 
Reports suggest however, that the lipid peroxidation product, 
malondialdehyde, may cross-link DNA on the same and op-
posite strands [5] via adenine and cytosine [6]. This may in 
theory contribute to carcinogenecity and mutagenecity in 
mammalian cells [7, 8].  
  LDL-cholesterol is more susceptible to oxidation in   
various pathologic conditions, which result in higher LPO 
(lipid peroxidation) during oxidative stress [9, 10]. HDL-
cholesterol, on the other hand, is able to counterbalance the 
oxidative damage of LDL-cholesterol on cell membrane and 
prevent LPO. It has been suggested that HDL-cholesterol 
prevents both enzymatic and nonenzymatic generation of   
O2
-, H2O2 and OH [11] and thus acts as an anticarcinogen 
and a powerful antioxidant.  
  There is evidence that cholesterol has a role in prostate 
disease. Swyer (1994) reported an increase level of choles-
terol in prostatic adenomas compared to normal tissue. Since 
then, many studies have supported a relationship between 
cholesterol in prostate tissues or secretions and benign or 
malignant prostate growth [12]. Magura et al. [13] conducted 
a hospital-based case-control study to examine the possible 
association between hypercholesterolemia and prostate can-
cer. Hypercholesterolemia was defined as total cholesterol 
greater than 5.17 (mmol/l). Univariate logistic regression 
demonstrated a significant association between hypercholes-
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confidence interval (CI): 1.19-2.27). This association changed 
only slightly after adjustment for age, family history of pros-
tate cancer, body mass index, type 2 diabetes, smoking, and 
multivitamin use. A significant association was also found 
between a low HDL level and prostate cancer (OR = 1.57, 
95% CI: 1.04-2.36). A high LDL level was associated with a 
60% increased risk for prostate cancer (OR = 1.60, 95% CI: 
1.09-2.34). .  
  The relationship between lipids and breast cancer is ob-
scure and there are conflicting studies as to whether there is 
an association between lipids breast cancer. The causes of 
breast cancer are not known, but presumably it occurs due to 
a complex interplay of genetic susceptibility and environ-
mental factors [14, 15]. Many studies have suggested that the 
relative risk of breast cancer is directly associated with the 
increase in dietary fat intake [16-22]. 
  Ray and Husain [17] demonstrated that plasma total cho-
lesterol, LDL-cholesterol and triglicerides (TG) were found 
to be significantly elevated among breast cancer patients as 
compared to the controls. On the other hand, plasma HDL-
cholesterol concentration was significantly decreased in 
breast cancer patients. The maximum increase in plasma 
total cholesterol was seen in breast cancer patients with stage 
IV when compared with controls. The Stepsenwol study re-
ported that lipids might primarily affect the gonads [7]. The 
high concentration of triglicerides may lead a decreased level 
of sex hormone-binding globulin, resulting in higher amount 
of free estradiol, which may likely to increase breast cancer 
risk [8]. The study by Shah et al. [23] aimed to examine the 
role of alterations in the lipid profile in breast cancer. Odds 
ratio analysis revealed that higher levels of total cholesterol 
and HDL were significantly associated with a reduction in 
breast cancer risk (p =0.01 and p =0.0001, respectively), 
whereas higher levels of VLDL and TG were significantly 
associated with increased breast cancer risk (p = .001 and p = 
.002, respectively). The alterations in lipid profile levels also 
showed a significant correlation with breast cancer risk, dis-
ease status, and treatment outcome [23]. 
  A relationship of plasma lipids with gynecologic cancer 
has also been reported (24. In patients with ovarian cancer, 
there was a large decrease in the plasma levels of triglyc-
erides (31%) and HDL-cholesterol (39%), with a moderate 
decrease in cholesterol (28%) and LDL-cholesterol levels 
(11%). In other gynecologic cancers, there was a significant 
decrease in plasma levels of the triglycerides (25%), choles-
terol (21%), and HDL-cholesterol levels (27%), but a non-
significant decrease in LDL-cholesterol (6.2%) when com-
pared with normal subjects. HDL-cholesterol was decreased 
in all gynecologic cancers [24].  
  Hypertryglyceridaemia may also predispose to malig-
nancy. Elevated triglycerides levels have been demonstrated 
in patients with several different types of cancer [18-20]. 
Alexopoulos  et al. [18] however, found a non-significant 
difference in serum triglycerides between controls and can-
cer patients. The exact mechanism by which hypertriglyc-
eridemia and decreased HDL-cholesterol concentration oc-
cur in patients with cancer is not known. It has, however, 
been suggested that lipoprotein lipase (LPL) may regulate 
the clearance of TG from blood to tissue and its activity in 
white adipose tissue is decreased in patients with cancer thus 
contributing to hypertriglyceridemia [21]. Since precursor 
particles of HDL-cholesterol are thought to derive from 
lipolysis of TG, and the LPL activity is decreased in cancer 
[22], increased plasma TG may be one of the factors that 
results in lower HDL-cholesterol concentration.  
  Early studies have reported that the hypolipidemia asso-
ciated with malignancy may have been due to the direct lipid 
lowering effect of tumor cells, some secondary malfunction 
of the lipid metabolism or secondary to antioxidant vitamins 
used in the treatment of the cancer [25-28]. An inverse trend 
between lower serum cholesterol and head neck as well as 
esophageal cancer has been reported [25-30]. Rose et al. [31] 
reported a 66% higher mortality rate in cancer patients with 
lower plasma cholesterol.  
 Patel  et al. [1] demonstrated significantly lower plasma 
total cholesterol, HDL – cholesterol, VLDL-cholesterol and 
triglycerides in patients with head and neck cancer and in 
those with oral precancerous conditions (OPC). A significant 
decrease in plasma total cholesterol and HDLC was observed 
in patients with cancer (p=0.008 and p=0.000, respectively) 
as well as in patients with OPC (p=0.014 and p=0.000, re-
spectively) as compared to the controls [1].  
  The lower levels of plasma cholesterol and other lipid 
constituents in patients with some types of cancer might be 
due to their increased utilization by neoplastic cells for new 
membrane biogenesis. Whether hypolipidemia at the time of 
diagnosis, is a causative factor or is a result of the cancer 
remains unanswered. Lower plasma lipid status however, 
may be a useful marker in the early neoplastic changes. 
 Yang  et al. [32] reported an association between LDL- 
cholesterol and cancer among patients with type 2 dibetes 
mellitus. A V-shaped risk relation between LDL cholesterol 
and all-site cancer was demonstrated. LDL cholesterol levels 
below 2.80 mmol/L and levels of at least 3.80 mmol/L were 
both associated with markedly elevated risk of cancer among 
patients who did not use statins. There was a 50% higher risk 
of cancer among patients with an LDL cholesterol level ei-
ther above or below these levels. The associations persisted, 
with a slight increase in hazard ratios, after exclusion of pa-
tients who had been followed for less than 2.5 years [32]. 
These observations suggest that the increased risk of cancer 
among patients with high and low LDL cholesterol were 
probably not attributable to undiagnosed cancer. 
ALTERATIONS IN LIPID PROFILE AFTER CANCER 
THERAPY  
  Prostate cancer is the leading cancer diagnosis and the 
second leading cause of cancer-related mortality in men in 
the USA. Men at risk of prostate cancer represent the same 
population of men who are at greatest risk for metabolic 
syndrome, diabetes mellitus, and coronary artery disease 
(CAD). In addition to risk factors for CAD that are applica-
ble to the general population, men with prostate cancer   
can be at increased risk for CAD due to long-term androgen 
deprivation therapy (ADT) administered as treatment for 
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  Androgen deprivation therapy decreases lean mass and 
increases fat mass. It also decreases insulin sensitivity while 
increasing LDL- cholesterol, HDL cholesterol and triglyc-
erides levels. [33]. One year of GnRH agonist therapy in a 
group of 40 men with prostate cancer was later found to 
cause significant increases in total cholesterol (9.0%), HDL 
cholesterol (11.3%), LDL cholesterol (7.3%) and triglyc-
erides (26.5%) [34]. In another study men experienced sig-
nificant increases in total cholesterol and HDL cholesterol 
during the first three months of GnRH agonist treatment 
[35].  
  Bexarotene has been approved for the treatment of cuta-
neous T cell lymphomas in patients refractory to systemic 
therapy. Associated hypertriglyceridaemia requires monitor-
ing, but can readily be managed with concomitant medica-
tion, such as fenofibrate [36]. 
  Patients suffering from acute lymphoblastic leukaemia 
(ALL) treated with asparaginase and corticosteroids are at 
risk of developing severe lipid abnormalities. Hypertriglyc-
eridemia has been successfully managed using plasmaphere-
sis [37]. Pancreatitis due to hypertriglyceridemia during as-
paraginase treatment for ALL can be prevented by, carrying 
out plasma exchange using fresh frozen plasma. This re-
duced both serum triglyceride and total cholesterol levels 
from 5430 mg/dL to 403 mg/dL and from 623 mg/dL to 204 
mg/dL, respectively [38]. Plasmapheresis appears to be safe 
and effective in reducing hypertriglyceridemia and prevent-
ing related complications in ALL. 
  Patients with malignant disease may need hormonal ther-
apy as primary or adjuvant treatment. Hormonal treatment 
may alter serum lipid levels and, therefore, may contribute to 
cardiovascular diseases in patients with cancer [39, 40]. Oes-
trogen therapy seems to have a mixed effect on serum lipid 
levels with a significant decrease in the levels of total choles-
terol and LDL-cholesterol, an increase in HDL-chlesterol, 
but an increase in triglyceride concentration [41, 42].  
  Short term treatment using progestogens decrease total 
cholesterol, LDL-cholesterol and HDL-cholesterol concen-
trations and increase TG levels. In long-term treatment, pro-
gestogens usually have a small impact on lipid profile [43, 
44]. 
  Tamoxifen remains one of the most effective agents in 
the treatment of breast cancer. The development of persistent 
side effects from chronic administration of tamoxifen how-
ever, remains a concern. Tamoxifen is a selective oestrogen 
receptor modulator, which binds to oestrogen receptors of 
tumour cells and prevents the binding of endogenous oestro-
gen [45]. In the study by Love et al. Tamoxifen decreased 
total cholesterol and LDL-cholesterol levels in postmeno-
pausal women [46].
  The long term effects of Tamoxifen 
therapy on the plasma lipoprotein concentration and lipid 
transfer activity in postmenopausal women diagnosed with 
breast cancer have been investigated [47]. A significant de-
crease in total and LDL - cholesterol levels and a moderate 
increase in HDL cholesterol levels were observed in plasma 
samples from postmenopausal women with breast cancer 
who were administered Tamoxifen for two years. No signifi-
cant differences in total and lipoprotein C and TG plasma 
levels were observed in samples from women with breast 
cancer who had never received tamoxifen. LTP I activity 
was significantly decreased in patients receiving Tamoxifen 
compared to patients who had never received tamoxifen 
[47].  
  A study in postmenopausal patients receiving adjuvant 
tamoxifen (10 mg/d) reported a significant increase in serum 
TG levels after 15 months. Although the increase remained 
within the reference range for most patients (n=102), severe 
hypertriglyceridemia developed in four patients after 6 
months [48].  
  These specific tamoxifen-induced effects may be impor-
tant for a number of reasons. Although the apparent decrease 
in total cholesterol and LDL- cholesterol levels reduce the 
risk of cardiovascular disease, the elevated levels of triglyc-
erides have been related to an increased risk of ischemic 
heart disease. 
  Tamoxifen has also been associated with hypertriglyc-
eridemia-induced acute pancreatitis [49-53]. These detrimen-
tal effects may be attributable to Tamoxifen also being a 
partial oestrogen agonist, a characteristic associated with the 
increased incidence of both thromboembolic events and en-
dometrial cancer [49-53].  
  Aromatase inhibitors which are also frequently used in 
treating breast cancer, block the cytochrome P450-dependent 
enzyme aromatase, preventing the conversion of androgens 
to oestrogens. These third-generation drugs (anastrozole, 
letrozole and exemestane) are alternative agents to tamoxifen 
for the treatment of postmenopausal women with hormone-
dependent breast cancer [54].  
  The effects of adjuvant anastrozole (1 mg/d), exemestane 
(25mg/d), or tamoxifen (20 mg/d) were investigated in 
postmenopausal women with operable breast cancer. Anas-
trozole resulted in a non-significant decrease in the levels of 
total cholesterol, LDL-cholesterol and TG, and a significant 
increase in HDL- cholesterol concentration [55]. Similar 
changes were observed after exemestane treatment, although 
the changes in HDL-cholesterol levels were not significant 
[56-58]. Long-term studies in postmenopausal women with 
advanced breast cancer demonstrated that anastrozole did not 
significantly change TC/HDL-C or LDL-C/HDL-C ratios 
[56-58]. 
STATIN TREATMENT AND MALIGNANCY 
  Although one recent analysis of a large cohort of patients 
treated with statins showed a greater risk of cancer with low 
LDL cholesterol levels [59], a more recent study reported 
otherwise [60]. There is a possibility that statins have anti-
cancer activity [61]. Yang et al. found that patients who used 
statins were less likely to develop cancer, less likely to die 
and less likely to have the composite outcome of all-site can-
cer and all-cause death. At enrolment, patients who used 
statins were more likely to have an LDL cholesterol level of 
at least 3.80 mmol/L but less likely to have a level of less 
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study of 30 076 patients started on a lipophilic statin after a 
myocardial infarction reported a reduction of one-quarter in 
the hazard ratio for cancer incidence with high-dose statin 
treatment [60]. The findings from observational studies how-
ever, are not supported by the results of a meta-analysis of 
clinical outcome trials conducted by the Cholesterol Treat-
ment Trialists’ Collaboration which reported no reduction   
in cancer incidence [62]. Also three meta-analyses showed 
that the use of statins, which inhibit cholesterol synthesis, 
was not associated with any change in the risk of developing 
cancer [63-65].  
  Nevertheless, their results cannot completely exclude 
longer term effects of statins as the mean duration of these 
trials was only five years. 
CONCLUSIONS 
  The mechanism for any link between cancer and choles-
terol remains controversial. The mevalonate pathway, which 
leads to cholesterol synthesis, can produce molecules such as 
the isoprenoids farnesol and geranylgeraniol, which are im-
portant for a number of signaling proteins such as the 
GTPases Ras and Rho [66]. The Ras and Rho proteins are 
known to be involved in cell proliferation, differentiation 
and apoptosis. Thus, the observations that elevated LDL cho-
lesterol level is associated with increased cancer risk are 
consistent with experimental findings that the mevalonate 
pathway may be associated with the development and pro-
gression of cancer [66]. The pathway for cholesterol synthe-
sis may produce various tumorigenic compounds. As choles-
terol serves as a precursor for the synthesis of many sex 
hormones there may be a link to an increased risk of various 
cancers.  
  Conversely, the underlying mechanism for the risk   
association between all-site cancer and low cholesterol level 
is not immediately obvious. One plausible explanation is   
that low LDL cholesterol may upregulate the activity or re-
sponsiveness (or both) of the mevalonate pathway in periph-
eral tissues. However the relation between low levels of   
LDL cholesterol and cancer remains controversial and its 
true mechanism remains elusive [65-68]. In the absence of 
definite biological mechanisms confirming that low choles-
terol levels increase the risk of cancer and given the results 
of randomized trials indicating no increased risk of cancer 
with the use of statins, lowering LDL cholesterol still re-
mains a top priority in the treatment of hypercholesterolemia 
[65-68].  
  The potential clinical utility of cholesterol fractions to 
predict cancer risk is still questionable. as there are differ-
ences between differenty types of cancer in the plasma lipid 
profile. The detailed study of cholesterol carrying lipoprotein 
transport and the efficiency of the receptor system may help 
in understanding the underlying mechanisms of regulation of 
plasma cholesterol concentrations in cancer [69-76]. 
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